Company / Cash & Equivalents
STANDARD BIOTOOLS INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$120.9M
FY2025
5-year range
$28.5M / $166.7M
FY2021-FY2025
Trend
-27.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $22M in FY2019 to $167M in FY2024.
Based on SEC 10-K filings.
$121M in FY2025 with a 5-year CAGR of +12.0%.
Improved from $52M to $121M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +14.1%
- 5-Year CAGR
- +12.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +12.0%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 27.5% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $120.9M | -27.5% |
| FY2024 | $166.7M | +222.5% |
| FY2023 | $51.7M | -36.4% |
| FY2022 | $81.3M | +185.8% |
| FY2021 | $28.5M | -58.5% |
| FY2020 | $68.5M | +216.3% |
| FY2019 | $21.7M | -77.3% |
| FY2018 | $95.4M | +227.6% |
| FY2017 | $29.1M | -13.6% |
| FY2016 | $33.7M | -4.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026